Tiotropium in chronic obstructive pulmonary disease [4]

New England Journal of Medicine

Volumn 360, Issue 2, 2009, Pages 186-

  Singh, Sonal ^a   Furberg, Curt D ^a   Loke, Yoon K ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; TIOTROPIUM BROMIDE;

CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FOLLOW UP; HUMAN; LETTER; LUNG CANCER; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STROKE; SUDDEN DEATH;

EID: 58249106770     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004;1:303-12.
2. Tashkin DP, UPLIFT Trial Investigators. UPLIFT safety broadcast. (Accessed December 16, 2008, at https://admin.na3.acrobat.com/-a747252205/ p36543734/.)
3. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695-703.